| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Zodasiran | ARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals) | Phase 3 Clinical | Roche Ltd | Dyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia | Details |
| LNA-043 | LNA-043 | Phase 2 Clinical | Novartis Pharma Ag | Knee Injuries; Osteoarthritis; Osteoarthritis, Knee | Details |
| Vupanorsen | ISIS-703802; PF-07285557 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| EDP-167 | EDP-167; EDP167 | Phase 2 Clinical | Eteng Pharmaceutical (Zhuhai) Co Ltd | Dyslipidemias; Homozygous familial hypercholesterolemia | Details |
| ALN-ANG3 | ALN-ANG3 | Phase 2 Clinical | Alnylam Pharmaceuticals Inc | Diabetic Nephropathies | Details |
| BW-00112 | BW-00112; BW00112 | Phase 2 Clinical | Shanghai Argo Biopharmaceutical Co Ltd | Dyslipidemias; Hypertriglyceridemia | Details |
| Solbinsiran | LY-3561774; DCR-CM-1; DCR-CM1 | Phase 2 Clinical | Dicerna Pharmaceuticals Inc | Cardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases | Details |
| JS-401 | JS-401; RP-912 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Hyperlipidemias; Metabolic Diseases | Details |
| VERVE-201 | VERVE-201 | Phase 1 Clinical | Broad Institute, Harvard University | Atherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia | Details |
| SYH-2070 | SYH2070; SYH-2070 | Phase 1 Clinical | Cspc Heibei Zhongrun Pharmaceutiacl Co Ltd | Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia | Details |
| NN-6491 | NN6491; NN-6491 | Phase 1 Clinical | Novo Nordisk A/S | Cardiovascular Diseases | Details |
| NNC0491-6075 | NNC0491-6075; NNC04916075 | Phase 1 Clinical | Novo Nordisk A/S | Dyslipidemias | Details |
| AZD-1705 | AZD1705; AZD-1705 | Phase 1 Clinical | Astrazeneca Plc, Parexel International Corp | Cardiovascular Diseases | Details |
| CTX-310 | CTX-310; CTX310 | Phase 1 Clinical | Crispr Therapeutics Ag | Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Evinacumab | REGN-1500 | Approved | Regeneron Pharmaceuticals Inc | Evkeeza | United States | Hypercholesterolemia; Homozygous familial hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2021-02-11 | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases | Details |